EP1243582A4
(en)
*
|
1999-12-24 |
2003-06-04 |
Kirin Brewery |
CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
|
RU2264389C3
(en)
|
2000-10-20 |
2018-06-01 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
NITROGEN-CONTAINING AROMATIC DERIVATIVES, THEIR APPLICATION, MEDICINE ON THEIR BASIS AND METHOD OF TREATMENT
|
AU2003249212C1
(en)
|
2002-07-15 |
2011-10-27 |
Symphony Evolution, Inc. |
Receptor-type kinase modulators and methods of use
|
WO2004039782A1
(en)
*
|
2002-10-29 |
2004-05-13 |
Kirin Beer Kabushiki Kaisha |
QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
|
JP4750701B2
(en)
*
|
2003-07-07 |
2011-08-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Malonamide derivatives
|
GB0317268D0
(en)
*
|
2003-07-23 |
2003-08-27 |
Viral Asa A |
Compounds
|
AU2013204031B2
(en)
*
|
2003-09-26 |
2016-10-27 |
Exelixis, Inc. |
c-Met modulators and methods of use
|
SI2392564T1
(en)
*
|
2003-09-26 |
2014-02-28 |
Exelixis, Inc. |
c-Met modulators and methods of use
|
CN100450998C
(en)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
Process for the preparation of urea derivatives
|
CA2553433A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
|
AU2005206571B8
(en)
*
|
2004-01-23 |
2010-09-02 |
Amgen Inc. |
Compounds and methods of use
|
RU2330021C2
(en)
*
|
2004-02-27 |
2008-07-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
New pyridine derivative and pyrimidine derivative (1)
|
ES2359836T3
(en)
*
|
2004-04-23 |
2011-05-27 |
Bristol-Myers Squibb Company |
MONOCICLIC HETEROCICLES AS QUINASA INHIBITORS.
|
US7459562B2
(en)
*
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
US7880000B2
(en)
|
2004-05-07 |
2011-02-01 |
Amgen Inc. |
Protein kinase modulators and method of use
|
WO2005121125A1
(en)
*
|
2004-06-09 |
2005-12-22 |
Pfizer Inc. |
Ether-linked heteroaryl compounds
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
US7173031B2
(en)
*
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7439246B2
(en)
*
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
US7977345B2
(en)
|
2004-07-02 |
2011-07-12 |
Exelixis, Inc. |
c-MET modulators and method of use
|
KR101257343B1
(en)
*
|
2004-07-30 |
2013-04-23 |
메틸진 인코포레이티드 |
Inhibitors of vegf receptor and hgf receptor signaling
|
WO2006030826A1
(en)
|
2004-09-17 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
JP2008521900A
(en)
*
|
2004-11-30 |
2008-06-26 |
アムジエン・インコーポレーテツド |
Quinolines and quinazoline analogues and their use as medicaments for the treatment of cancer
|
AU2006229343A1
(en)
*
|
2005-03-28 |
2006-10-05 |
Kirin Pharma Kabushiki Kaisha |
Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
|
EP1874759A4
(en)
*
|
2005-04-06 |
2009-07-15 |
Exelixis Inc |
C-met modulators and methods of use
|
JO2787B1
(en)
*
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Substituted Amid derivatives & methods of use
|
BRPI0610322B8
(en)
*
|
2005-05-20 |
2021-05-25 |
Methylgene Inc |
vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition
|
CA2608726C
(en)
*
|
2005-05-20 |
2013-07-09 |
Methylgene Inc. |
Inhibitors of vegf receptor and hgf receptor signaling
|
CA2611688A1
(en)
|
2005-06-30 |
2007-01-11 |
Amgen Inc. |
Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
|
EP2281901B1
(en)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Anti-tumour pharmaceutical composition with angiogenesis inhibitors
|
DK1889836T3
(en)
|
2005-08-24 |
2013-08-19 |
Eisai R&D Man Co Ltd |
Hitherto unknown pyridine derivative and pyrimidine derivative
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
CN101522687A
(en)
*
|
2006-01-30 |
2009-09-02 |
阿雷生物药品公司 |
Heterobicyclic thiophene compounds and methods of use
|
US7868177B2
(en)
|
2006-02-24 |
2011-01-11 |
Amgen Inc. |
Multi-cyclic compounds and method of use
|
MX2008011220A
(en)
|
2006-03-07 |
2008-09-11 |
Array Biopharma Inc |
Heterobicyclic pyrazole compounds and methods of use.
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
WO2008035209A2
(en)
*
|
2006-05-30 |
2008-03-27 |
Methylgene Inc. |
Inhibitors of protein tyrosine kinase activity
|
EP2032538A2
(en)
*
|
2006-06-08 |
2009-03-11 |
Array Biopharma, Inc. |
Quinoline compounds and methods of use
|
JP4948913B2
(en)
*
|
2006-06-16 |
2012-06-06 |
上野製薬株式会社 |
Method for producing naphthalenecarboxylic acid amide
|
WO2008023698A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Eisai R & D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
KR101472600B1
(en)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Antitumor agent for undifferentiated gastric cancer
|
US7790885B2
(en)
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
MX2009006543A
(en)
|
2006-12-20 |
2009-06-26 |
Amgen Inc |
Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer.
|
WO2008093855A1
(en)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
DE102007026341A1
(en)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
MX2010002427A
(en)
|
2007-08-29 |
2010-03-30 |
Methylgene Inc |
Inhibitors of protein tyrosine kinase activity.
|
EP2220078B1
(en)
*
|
2007-10-29 |
2013-05-22 |
Amgen, Inc |
Benzomorpholine derivatives and methods of use
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
JP2009132660A
(en)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
Composition for treating esophageal cancer
|
US20090227556A1
(en)
*
|
2008-01-31 |
2009-09-10 |
Eisai R&D Management Co., Ltd. |
Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
|
WO2009104520A1
(en)
*
|
2008-02-18 |
2009-08-27 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Method for producing phenoxypyridine derivative
|
BRPI0906186A2
(en)
|
2008-03-17 |
2015-09-22 |
Ambit Biosciences Corp |
compound and use of a compound
|
CN101998951B
(en)
*
|
2008-04-10 |
2013-07-17 |
大鹏药品工业株式会社 |
Acylthiourea compound or salt thereof, and use thereof
|
AR073231A1
(en)
*
|
2008-08-29 |
2010-10-20 |
Genentech Inc |
DIAGNOSTIC METHODS AND TREATMENTS FOR VEGF INDEPENDENT TUMORS (VASCULAR ENDOTELIAL GROWTH FACTOR)
|
EP2340244A4
(en)
*
|
2008-10-14 |
2012-07-25 |
Ning Xi |
Compounds and methods of use
|
CN102256493A
(en)
*
|
2008-10-29 |
2011-11-23 |
迪赛孚尔制药有限公司 |
Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
AU2009313970A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Exelixis Inc. |
Methods of preparing quinoline derivatives
|
DE102009003975A1
(en)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
CN110818633A
(en)
|
2009-01-16 |
2020-02-21 |
埃克塞里艾克西斯公司 |
Malate and crystal form thereof
|
KR20110133048A
(en)
*
|
2009-03-21 |
2011-12-09 |
닝 시 |
Amino ester derivatives, salts thereof and methods of use
|
KR101106050B1
(en)
*
|
2009-03-25 |
2012-01-18 |
한국과학기술연구원 |
Aminoquinoline compound, preparation method thereof and pharmaceutical composition containing same
|
AU2010254053A1
(en)
*
|
2009-05-28 |
2011-12-01 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrazole inhibitors of c-Met protein kinase
|
CA2768370A1
(en)
|
2009-07-17 |
2011-01-20 |
Exelixis, Inc. |
Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
|
UA108618C2
(en)
|
2009-08-07 |
2015-05-25 |
|
APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
|
CN102958523B
(en)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
WO2012008563A1
(en)
|
2010-07-16 |
2012-01-19 |
協和発酵キリン株式会社 |
Nitrogenated aromatic heterocyclic ring derivative
|
WO2012044577A1
(en)
|
2010-09-27 |
2012-04-05 |
Exelixis, Inc. |
Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
|
WO2012144463A1
(en)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Therapeutic agent for tumor
|
ES2705950T3
(en)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
|
CN102643268B
(en)
*
|
2011-12-30 |
2014-05-21 |
沈阳药科大学 |
Quinolines and cinnolines and their applications
|
WO2013143376A1
(en)
*
|
2012-03-26 |
2013-10-03 |
武汉盛云生物医药科技有限责任公司 |
Quinoline compounds containing 1,2,4-triazine-3,5-dione and use thereof
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2013180128A1
(en)
*
|
2012-05-28 |
2013-12-05 |
協和発酵キリン株式会社 |
4-[4-(5-membered aromatic heterocyclic carbonyl ureide)phenyloxy]quinoline derivative
|
JP6181172B2
(en)
|
2012-06-26 |
2017-08-16 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
N- [4- (Quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides as androgen receptor antagonists, their preparation and use as pharmaceuticals
|
WO2014038881A2
(en)
*
|
2012-09-06 |
2014-03-13 |
씨제이제일제당 (주) |
Protein kinase inhibitor comprising pyridine derivatives
|
US9334239B2
(en)
|
2012-12-21 |
2016-05-10 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
US9353122B2
(en)
*
|
2013-02-15 |
2016-05-31 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
US9695184B2
(en)
|
2013-02-15 |
2017-07-04 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
KR102333718B1
(en)
*
|
2013-03-15 |
2021-12-01 |
데시페라 파마슈티칼스, 엘엘씨. |
N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
|
ES2687968T3
(en)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarkers to predict and evaluate the reactivity of subjects with endometrial cancer to compounds with lenvatinib
|
CA2943329A1
(en)
|
2014-03-24 |
2015-10-01 |
Genentech, Inc. |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
EP2974729A1
(en)
|
2014-07-17 |
2016-01-20 |
Abivax |
Quinoline derivatives for use in the treatment of inflammatory diseases
|
KR102329681B1
(en)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
High-purity quinoline derivative and method for manufacturing same
|
US20180028662A1
(en)
|
2015-02-25 |
2018-02-01 |
Eisai R&D Management Co., Ltd. |
Method for Suppressing Bitterness of Quinoline Derivative
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
US11369623B2
(en)
|
2015-06-16 |
2022-06-28 |
Prism Pharma Co., Ltd. |
Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
|
KR102587702B1
(en)
|
2015-08-20 |
2023-10-12 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
tumor treatment
|
KR20180086187A
(en)
|
2015-10-05 |
2018-07-30 |
더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 |
Clearance of protein aggregates including phospholipase D and tau, and treatment of protein diseases
|
EP3246028A1
(en)
*
|
2016-05-18 |
2017-11-22 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinoline compounds for increasing insuline release
|
US10799503B2
(en)
|
2016-12-01 |
2020-10-13 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
KR102323255B1
(en)
|
2017-02-15 |
2021-11-08 |
다이호야쿠힌고교 가부시키가이샤 |
pharmaceutical composition
|
JP2020519576A
(en)
|
2017-05-16 |
2020-07-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Treatment of hepatocellular carcinoma
|
WO2019049956A1
(en)
*
|
2017-09-08 |
2019-03-14 |
大鵬薬品工業株式会社 |
Antitumor agent and antitumor effect potentiator
|
CN109824587A
(en)
*
|
2017-11-23 |
2019-05-31 |
上海翔锦生物科技有限公司 |
The preparation method of tyrosine kinase inhibitor XJF007 and its intermediate
|
US11407760B2
(en)
|
2018-02-11 |
2022-08-09 |
Beijing Scitech-Mq Pharmaceuticals Limited |
Dioxinoquinoline compounds, preparation method and uses thereof
|
US11702425B2
(en)
|
2018-08-01 |
2023-07-18 |
Agency For Science, Technology And Research |
Bicyclic compounds as kinase modulators, methods and uses thereof
|
EP3669873A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Quinoline derivatives for use ine the traeatment of inflammation diseases
|
KR20210119411A
(en)
|
2018-12-28 |
2021-10-05 |
데시페라 파마슈티칼스, 엘엘씨. |
CSF1R inhibitors for use in cancer treatment
|
CN111840299A
(en)
*
|
2019-04-30 |
2020-10-30 |
武汉盛云生物医药科技有限责任公司 |
Application of quinoline compound in preparation of cancer treatment drug
|